What is Touchlight Genetics?
Touchlight Genetics, a London-based biotechnology firm established in 2007, is at the forefront of discovering and developing innovative DNA-based genetic medicines. The company's core innovation lies in its proprietary "doggybone" or dbDNA technology, a novel synthetic DNA vector designed for enhanced efficacy in DNA vaccines and gene therapies. This advanced platform positions Touchlight Genetics as a key player in the rapidly evolving landscape of genetic medicine.
How much funding has Touchlight Genetics raised?
Touchlight Genetics has raised a total of $58M across 1 funding round:
Other Financing Round
$58M
Other Financing Round (2021): $58M with participation from Bridford Investments Limited
Key Investors in Touchlight Genetics
Bridford Investments Limited
Bridford Investments Limited is an investor participating in the funding round, with their specific investment focus not detailed.
What's next for Touchlight Genetics?
With a major enterprise-level funding context and a recent strategic investment, Touchlight Genetics is poised for significant expansion and advancement in its research and development pipeline. The company's focus on dbDNA technology suggests a strategic direction towards scaling its capabilities in producing DNA-based therapeutics and vaccines. Future endeavors will likely involve further clinical trials, potential partnerships, and the commercialization of its innovative genetic medicine solutions, solidifying its position in the biotechnology sector.
See full Touchlight Genetics company page
